Monod Bio Receives $1.5M Gates Foundation Grant for TB Diagnostic Development
Seattle startup will use funding to develop urine-based tuberculosis test using engineered NovoBodies technology for low-resource settings.
Seattle startup will use funding to develop urine-based tuberculosis test using engineered NovoBodies technology for low-resource settings.
Company showcases FDA-cleared ProNephro AKI test as acute kidney injury remains key focus for laboratory medicine professionals.
The Alzheimer's Association released its first clinical practice guideline on the use of blood-based biomarker tests.
Two studies will evaluate circulating tumor DNA as a guide for post-surgical cancer treatment decisions.
Clinical labs help drive early HIV detection and support efforts to prevent its spread.
The new noninvasive prenatal test addresses testing gaps when biological fathers are unavailable for carrier screening by analyzing fetal DNA from maternal blood samples.
New research demonstrates BAT outperforms standard allergy tests in children under 2, potentially reducing need for oral food challenges by nearly half.
Lipoprotein(a), or Lp(a), is a genetically determined and under-recognized cardiovascular disease risk factor.
The surface-enhanced Raman spectroscopy platform can detect amyloid beta biomarkers at ultra-low concentrations in body fluids, potentially enabling earlier diagnosis and monitoring of disease progression.
It's essential to integrate point-of-care testing devices cautiously alongside traditional laboratory tests to ensure robust diabetes management.
With the acquisition, Quest will now provide dialysis lab testing for independent clinics that were previously served by Spectra Laboratories.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
A multicenter study found that early sepsis risk testing at triage led to more ED discharges and lower inpatient bed use without compromising patient safety.